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Engineering HIV Immunogens to Elicit IOMA-like 
Antibodies Targeting the CD4 Binding Site
Harry Gristick 1, Jelle van Schooten 1, Harald Hartweger 2, Morgan 
Abernathy 1, Jimena Pavlovitch-Bedzyk 1, Amelia Escolano 2, Anthony 
West Jr.1, Michel Nussenzweig 2, Pamela Bjorkman 1
1Caltech, United States, 2Rockefeller University, United States
Background: The most effective way to control the AIDS epidemic 
would be through active vaccination. The current focus of HIV 
vaccine design is induction of broadly neutralizing antibodies (bNAbs) 
against the HIV Envelope protein (Env) that neutralize the majority of 
circulating viral strains. Due to their breadth and potency, the most 
desirable bNAbs to elicit through immunization are the VRC01-class 
bNAbs that target the conserved host receptor (CD4) binding site 
(CD4bs). VRC01-class bNAbs mimic CD4 binding to share a common 
mode of gp120 binding and glycan accommodation using a VH1-2*02-
derived variable heavy (VH) domain. While attractive candidates for 
immunogen design, features of VRC01-class bNAbs such as a high 
degree of somatic hypermutation (SHM) and a short (5-residue) light 
chain (LC) complementarity determining region 3 (CDRL3) (found in 
only 1% of human LCs) suggest they might be difficult to elicit through 
vaccination. We recently published a structural characterization of 
a novel VH1-2*02-derived CD4bs bNAb, named IOMA, that is an 
attractive target for immunogen design due to its relatively low levels 
of SHMs and normal-length CDRL3 (8 residues). Here we describe 
our work to design an immunogen that elicits IOMA-like antibodies 
by engineering a gp120 from the 426c Env.
Methods: We used a yeast display approach coupled with multiple 
rounds of enrichment by fluorescent-activated cell sorting (FACS) 
to select gp120 variants that bind to the inferred germline of IOMA 
(IOMA iGL).
Results: Binding studies using enzyme-linked immunosorbent assays 
(ELISAs) and surface plasmon resonance (SPR) demonstrated that 
our novel gp120 immunogens bind to IOMA iGL with micromolar 
affinity.
Conclusions: We will present the results of immunization experiments 
using these novel immunogens in mouse models. 
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Vaccine Induction of VRC01-class Neutralizing 
Antibodies in a Knock-in Mouse Model
Xuejun Chen 1, Stephen D. Schmidt 1, Hongying Duan 1, Cheng Cheng 1, 
Nicole Doria-Rose 1, Ming Tian 2, Frederick W. Alt 2, John R. Mascola 1
1National Institute of Allergy and Infectious Diseases, United States, 
2Boston Children’s Hospital, United States
Background: Elicitation of VRC01-class neutralizing antibodies (Abs) 
is a major goal of HIV-1 vaccine design. Despite recent progress made 
using transgenic mouse models in initial activation of VRC01-class 
B cell precursors and elicitation of neutralizing VRC01-class, few of 
the elicited Abs can neutralize viruses with the N276 glycan that is 
present in over 95% of the circulating HIV strains.
Methods: To assess immunogens and immunization regimens, we 
used a unique double knock-in mouse model that expresses the 
human VH1-2 gene segment in combination with diverse mouse 
DHand JHsegments via V(D)J recombination and a human VK3-20 
gene segment attached to the VRC01 mature CDRL3. We tested 
two sequential immunization strategies: 1) homologous boosts with 
differentially deglycosylated gp120 cores and 2) heterologous boosts 
with gp120 cores from different strains. Immune sera were tested for 
neutralization. Monoclonal Abs were isolated at different time points 
and tested for neutralization.
Results: Both immunization strategies elicited detectable serum 
neutralizing titers against seven selected virus strains including those 
with an intact N276 glycan. Single B cell sorting with an engineered 
outer domain (eOD-GT8) probe and its CD4bs knock out variant led 
to isolation of various VRC01-class lineages that neutralized mostly 
N276-glycan deficient viruses. By adding a third probe, BG505.
SOSIP, we isolated a VRC01-class monoclonal antibody lineage with 
26 somatic mutations in the VHregion, and it neutralized five wild 
type viral strains with an intact N276 glycan, with the IC50 in the 
range of 0.8-28 µg/ml.
Conclusions: We elicited neutralizing VRC01-class Ab that can 
neutralize N276 glycan-containing viruses by sequential immunization 
in a knock-in mouse model expressing a repertoire of VRC01-class 
precursors with diverse CDRH3s. This work provides proof of 
concept that even highly somatic mutated broadly-neutralizing Abs 
like the VRC01-class Abs can be elicited through rationally designed 
sequential immunization. 
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